The HIV Prevention Pipeline

This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.

GPP Body of Evidence

A clearinghouse of case studies and analyses demonstrating the power of GPP

Since its first draft, the GPP guidelines have been adopted and used in HIV research and far beyond. AVAC has collected this body of evidence for GPP to demonstrate the power of GPP, to show how GPP can be measured and replicated, and to offer GPP training, tools and connection to everyone involved in the research enterprise. Visit here.

Inclusion of Pregnant and Lactating People in HIV Research

What you need to know 

Produced and hosted by Jeanne Baron

People who are pregnant or lactating (PLP) have historically been excluded from research because of concerns for the developing fetus. But this has led to a dearth of data on new interventions against health threats for this population. In the case of HIV, pregnancy raises the risk of acquiring HIV by up to three times, but providers often do not have the data to know whether a new intervention is safe or how it will work for pregnant patients. As a result, PLP and their physicians are left to make difficult decisions around the use of proven HIV prevention products as they await more data specific to pregnancy and lactation. 

But change is in the air. Champions for the inclusion of PLP in research are paving the way for a paradigm shift—one that will redefine this population from needing protection from research to being better protected through research. In this episode of Px Pulse, AVAC’s Manju Chatani-Gada takes us through conversations with a trial participant who became pregnant, researchers, policymakers and donors to understand why this population gets excluded, the impact it has and what to do about it.   

Tune it to hear:

  • Dr. Anne Drapkin Lyerly, Principal Investigator of the PHASES Project to advance equitable inclusion of pregnant women in HIV research and its follow-on project, PREPARE, focused on ethical HIV research in adolescents who are pregnant. 
  • Elisia Madende, trial participant in the HPTN 084 trial in Zimbabwe 
  • Dr. Ashley Lima, Health Science Specialist and Lead Technical Advisor for Socio-behavioral Research — USAID Office of HIV/AIDS Research Division 
  • Dr. Takunda Sola, HIV Prevention and Key Populations Medical Officer — Zimbabwe MoH AIDS/TB Unit 

Links:

Advocacy Resources:

Community Manifesto for HIV Long-Acting Injectable PrEP in Europe

This document stems from a March 2023 consensus meeting in Paris involving regional and international HIV prevention organizations and activists. Four main pillars were identified to promote new PrEP technologies and expand access to long-Acting injectable PrEP in Europe. These pillars should be implemented simultaneously and also aim to broaden PrEP accessibility beyond LA-CAB.

The Architecture for Pandemic Prevention, Preparedness, & Response (PPPR): Views from Civil Society Leaders on the UN High Level Meetings (Guest Essay)

AVAC’s Executive Director along with partners from the Coalition of Advocates for Global Health and Pandemic Preparedness penned an essay to make the case of meaningful investment in Pandemic Preparedness while referencing continued failures of the COVID-19 pandemic. Read the full essay here.

HIV Prevention Choice Manifesto

The HIV Prevention Choice Manifesto emphasizes community-led leadership and the importance of choice in HIV prevention for African women and girls. The manifesto advocates for universal access to a broad range of biomedical tools for HIV prevention and underscores the transformative potential when African women and girls lead advocacy and response efforts in HIV healthcare.

More information and background on the manifesto is available on our blog.

Px Wire May 2023

Volume 13, Number 2

PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of PxWire.

PEPFAR at 20: Keeping the promise

2023 is a big year for PEPFAR. Considered one of the greatest US foreign policy and global development achievements of the century, the program has saved upwards of 25 million lives since it launched in 2003. But PEPFAR is marking its 20th anniversary while fighting for its future.  

Its authorization expires September 30. Until a couple of months ago, most expected smooth sailing in the US Congress for a five-year reauthorization of the program. PEPFAR has enjoyed deep and broad bipartisan support since its founding. Evangelical Christians, staunch conservatives, DC Democrats, progressive HIV activists, and public health leaders have championed PEPFAR, year in and year out. But a handful of Republicans, including past PEPFAR allies, are pulling reauthorization into high-stakes partisan politics. 

In this episode, Px Pulse talks to some of the people who put PEPFAR dollars into action and to global health leaders who explain why PEPFAR’s approach has been so effective, and what’s at stake in this debate. 

Tune in to hear:

  • Ilda Kuleba from Mothers 2 Mothers talks about the impact of their work across 10 countries, training and employing HIV positive mothers as peer healthcare workers.
  • Dr. James Mukabi of World Vision’s Kenya program talks about how this Christian relief organization has changed the lives of thousands of orphans and other populations who are vulnerable to HIV. 
  • Tom Hart, President of the One Campaign, which was founded by the rock star Bono, to be an early champion of PEPFAR and other poverty fighting efforts talks about PEPFAR’s accomplishments at the global level and what’s next as congress debates reauthorizing the program.

Links:

Advocacy Resources:

Media:

Sexually Transmitted Infections

An Introductory Fact Sheet

This factsheet provides basic information on sexually transmitted infections (STIs), and a snapshot on the global status of STIs in the context of HIV prevention and global health equity.

AVAC Advocacy Fellows Program Instructions and Forms

This packet contains application instructions and forms for prospective applicants of the Fellows Program. This file is available as a PDF and as a Word document. For more information on the Advocacy Fellows program, visit www.avac.org/fellows.